News Phenex receives 1.4 Mio Euro BioChance Grant Phenex AG develops novel indications for FXR-targeted drugs and wins Prof. Dr. Michael Trauner as…PhenexJuly 2, 2009
News Prof. Dr. Bernd Wetzel becomes Head of Phenex´ Scientific Advisory Board Phenex AG benefits from Prof. Wetzel´s longstanding experience in research and early clinical development Ludwigshafen,…PhenexApril 8, 2009
News Phenex AG and Biogen Idec enter into a milestone-based target to lead collaboration Biogen Idec uses Phenex´ expertise to identify novel ligands for an undisclosed nuclear receptor Ludwigshafen,…PhenexDecember 3, 2008
News Phenex AG closes 11,5 M USD (8,2 M Euro) financing round A Syndicate of institutional and private investors provides funding for the development of Phenex´ drug…PhenexOctober 2, 2008
News Phenex AG provides drug profiling services to Sanofi Aventis Phenex uses its Nuclear Receptor assay battery and its SNuRM® platform to analyze compounds from…PhenexMay 9, 2007
News Phenex AG provides compound profiling services to BayerSchering Pharma AG Phenex AG provides compound profiling services to BayerSchering Pharma AG Ludwigshafen, Germany, February 8th, 2007…PhenexFebruary 8, 2007
News Phenex AG obtains four patents relevant for its drug discovery efforts The nuclear receptor-based drug discovery company starts to build a broad patent estate on FXR-…PhenexMarch 8, 2006
News Phenex AG closes its first financing round with a total volume of 4,2 M Euro equinet Venture Partners and KfW become shareholders in Phenex; additional funding comes from BioChance plus…PhenexOctober 11, 2005
News Phenex AG widens customer base, maintains profitability and recruits further laboratory staff The Nuclear Receptor Research Company strengthens its service business while heading for a funding round…PhenexJuly 28, 2005
News PheneX licenses Nuclear Receptor Research Toolbox to Roche PheneX provides a copy of its comprehensive Nuclear Receptor Research tool and clone collection to…PhenexMay 14, 2004